LONDON – Biosceptre Ltd. announced positive results from a U.S. phase I study of its lead antibody, BIL-010t, providing proof of concept for what the company said is a highly specific target found in at least 20 different cancers, and paving the way for a £20 million (US$34.2 million) funding round to take two products through to phase IIb development.